Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index; 65 of the 134 sources its claims cite were checked for support.

Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis

Open access
Crupi, Francesca, Caroprese, Jessica, Mannelli, Francesco · 2025 · Frontiers in Allergy

Abstract

Serum tryptase level has long been used as a biomarker in clinical practice to suspect mast-cell associated disorders. Basal serum tryptase (BST) above 20 ng/ml represents a minor criterion according to WHO and ICC for the diagnosis of systemic mastocytosis (SM) although normal BST value does not exclude the diagnosis. Nevertheless, BST can be elevated also due to non-SM related diseases as well as hereditary alpha-tryptasemia (H α T), an autosomal dominant germline condition that consists in the increase of the number of copies of the TPSAB1 gene encoding the alpha isoform of tryptase. The prevalence of H α T is estimated at around 5% of the general population. Individuals with H α T genotype can be asymptomatic; however, some of them can experience a range of symptoms with a large variability in type and severity, posing a problem of differential diagnosis with SM. The increasing awareness on a potentially SM underlying diverse clinical manifestations has led to excessive BST testing by several specialists, a trend that risks over interpreting some borderline results. The interpretation of elevated BST should thus be carefully appraised in specific clinical contexts on individual basis. This review is intended to examine the existing literature on this topic and offers a guide for interpreting the BST to rationalize the application of invasive diagnostic procedures.

Overview

CoChat Summary

TL;DR

This review argues that basal serum tryptase (BST) must be interpreted in clinical context because hereditary alpha-tryptasemia (HαT) and other conditions can elevate BST, confounding systemic mastocytosis (SM) diagnosis. It proposes using REMA score, peripheral blood KIT D816V testing, and HαT genotyping to rationalize invasive diagnostics, while noting BST >20 ng/ml is a minor WHO/ICC criterion but normal BST does not exclude SM.

Key findings

  • BST normal values have been reported as 1–11.5 ng/ml, while ECNM/AIM proposed a normal range of 1–15 ng/ml including asymptomatic HαT individuals; BST >20 ng/ml is a minor diagnostic criterion for SM and >200 ng/ml is a B-finding for smoldering SM. HαT prevalence is estimated at around 5% in the general population and up to 12%–20% in SM patients, with each extra TPSAB1 copy adding approximately 9–10 ng/ml to BST.
  • HαT can confound BST interpretation; several empirical correction formulae exist (Valent, Lyons, Chollet, Chovanec), but all are still to be validated prospectively. HαT may act as a clinical amplifier in SM: severe episodes were twice more frequent in individuals with both SM and HαT than in those with SM without HαT.
  • KIT D816V is present in over 90% of SM cases. Peripheral blood testing shows a discordance rate of 5%–10% versus bone marrow; in a PIONEER post hoc analysis, central ddPCR detected KIT D816V in 37/39 (95%) PB samples versus 11/39 (28%) by NGS and 30/39 (80%) locally. Negative predictive value was approximately 40% in patients with BST levels between 5 and 30 ng/ml.
  • Scoring systems include REMA, NICAS, Fuchs, and OSTEO. For patients without mastocytosis in the skin, ECNM recommends bone marrow biopsy when BST is greater than 25–30 ng/ml, REMA score is ≥2, or KIT D816V is detected in PB; in low REMA score (<2), no clear mediator-related symptoms, and elevated BST alone, initial PB KIT D816V and HαT testing are suggested, with SM reasonably excluded if KIT is negative and HαT genotype is confirmed.

Methods

  • Narrative review of existing literature on BST interpretation in suspected SM, HαT, KIT D816V testing, and scoring models; no primary patient cohort or systematic search is described.
  • Synthesizes diagnostic criteria from the 2022 ICC and WHO 5th edition, HαT genetics, tryptase thresholds, KIT assay performance, and scoring systems including REMA, NICAS, Fuchs, and OSTEO.
  • Proposes a basic algorithm for suspected SM based on REMA score, typical skin lesions, BST >15 ng/ml, PB KIT D816V testing, and HαT testing.

Limitations

  • Stated: all attempts to adjust BST for HαT are empirical and still to be validated prospectively; correlations between HαT and severe anaphylaxis are debated and need confirmation in larger datasets; urinary mediator findings require further validation.
  • Stated: despite improved KIT variant detection in PB, major limitations remain, and patients with very low disease burden classified as MMAS/cMCAS show the greatest BM/PB KIT discrepancies and remain a grey zone.
  • Evident: as a narrative review, no systematic search or quantitative synthesis is reported, and recommendations rely on cited literature and expert consensus rather than new primary data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/falgy.2025.1592001

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Possible combinations of genotypes for TPSB2 and TPSAB1. Adapted from Sordi et al. JACI, 2023.
Figure 1 Possible combinations of genotypes for TPSB2 and TPSAB1. Adapted from Sordi et al. JACI, 2023.CC BY · PubMed Central
Figure 2 Basic algorithm for patients with suspected SM. In patients with REMA score ≥2 and/or typical skin lesions and/or suggestive signs of SM, a BM examination should be performed to confirm or exclude SM regardless of BST value. In absence of these findings within BST value >15 ng/ml, we suggested an initial evaluation of KIT D816V in PB and (if available) HαT testing. When KIT D816V is detectable, BM study is recommended. BST, basal tryptase level; REMA, red Espanola de Mastocitosis; MIS, mastocytosis in the skin; SM, systemic mastocytosis; HαT, hereditary alpha tryptasemia; TPSAB1, tryptase alpha/beta 1; PB, peripheral blood; BM, bone marrow.
Figure 2 Basic algorithm for patients with suspected SM. In patients with REMA score ≥2 and/or typical skin lesions and/or suggestive signs of SM, a BM examination should be performed to confirm or exclude SM regardless of BST value. In absence of these findings within BST value >15 ng/ml, we suggested an initial evaluation of KIT D816V in PB and (if available) HαT testing. When KIT D816V is detectable, BM study is recommended. BST, basal tryptase level; REMA, red Espanola de Mastocitosis; MIS, mastocytosis in the skin; SM, systemic mastocytosis; HαT, hereditary alpha tryptasemia; TPSAB1, tryptase alpha/beta 1; PB, peripheral blood; BM, bone marrow.CC BY · PubMed Central

Verification

Claims the paper makes

49 Valid · 3 Not valid · 26 Not checked · 12 Own results and interpretations

19 more claims · 8 with their cited sources checked

Create a free account to see all 90 claims and to verify the 5 references still open.

See all claims — free account
  • It may state two separate claims as one. 27
  • Probably not a substantial claim. 56

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 72 references

Cited by

See all 2

Metadata

Authors
Crupi, F., Caroprese, J., & Mannelli, F.
Affiliations
Azienda Ospedaliero-Universitaria Careggi (IT)
Corresponding author
Mannelli, Francesco
Venue
Frontiers in Allergy
Published
2025-05-12
Volume
6
Pages
1592001-1592001
ISSN
2673-6101 (ISSN-L)
OpenAlex
W4410282155
Cited by
2
References
72
Citations by year
2026: 1 · 2025: 1
FWCI
0.18
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Allergy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Florence Research (University of Florence) (submittedVersion, other-oa)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords
systemic mastocytosis, hereditary alpha-tryptasemia, differential diagnosis, diagnostic criteria, overuse of diagnostic testing, mast cell disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis. https://app.cochat.ai/papers/10.3389/falgy.2025.1592001
The paper
Crupi, F., Caroprese, J., & Mannelli, F. (2025). Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis. Frontiers in Allergy. https://doi.org/10.3389/falgy.2025.1592001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.